Clinical Trials Logo

B-cell Lymphoma Recurrent clinical trials

View clinical trials related to B-cell Lymphoma Recurrent.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06378190 Recruiting - Clinical trials for B-cell Lymphoma Recurrent

Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology

TranspoCART19
Start date: March 11, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical trial is to to evaluate the safety and efficacy of TranspoCART19 in patients with relapsed/refractory B-lymphoma. The main questions it aims to answer are: Maximum tolerated dose (MTD) Response rates Participants will be treated with the investigational medicinal product and will be followed for 36 months.

NCT ID: NCT05318963 Recruiting - Clinical trials for B-cell Lymphoma Refractory

Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma

Start date: March 14, 2022
Phase: Phase 1
Study type: Interventional

A phase I, open-label clinical study to evaluate the safety, tolerability, and efficacy of LCAR-AIO, a triple-targeted cell preparation targeting CD19/CD20/CD22, in patients with relapsed/refractory B-cell lymphoma.

NCT ID: NCT04747093 Recruiting - Clinical trials for B-cell Acute Lymphoblastic Leukemia

Induced-T Cell Like NK Cells for B Cell Malignancies

Start date: January 29, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Relapsed and refractory B cell malignancies show unfavorable prognosis, especially for adult patients. Now, there is no standard management for these patients. Induced-T cell-like NK cells with chimeric antigen receptor (CAR-ITNK cells) is a promising treatment option for treating B cell derived malignancy. The purpose of this study is to evaluate the efficacy and safety of CAR-ITNK cells infusions in patients with relapsed and refractory B cell malignancies.

NCT ID: NCT03853616 Recruiting - Clinical trials for B-cell Lymphoma Refractory

MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)

Start date: November 26, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase l/ll multi-centric, single arm, prospective open, dose-escalation study in patients with relapsed or refractory CD19-positive B cell malignancies (ALL, NHL, CLL). The trial will include adult and pediatric patients. The trial consists of 2 parts: Part I and Part II. In total approximately 48 patients will be included in Part I of the trial. There will be three individual cohorts, defined by disease biology: pediatric ALL and aggressive pediatric NHL (Cohort 1), adult ALL (Cohort 2) and adult NHL/CLL (Cohort 3).

NCT ID: NCT03757000 Recruiting - Clinical trials for B-cell Chronic Lymphocytic Leukemia

A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies

Start date: December 25, 2017
Phase: Phase 1
Study type: Interventional

Protocol YY-20394-001 is a phase I open-label, first in human, dose escalation study to assess the tolerability, pharmacokinetics (PK) and efficacy of YY-20394 in patients with relapse or refractory B cell malignant hematological tumor.